title: Androgen deprivation therapy for prostate cancer: implications for cardiometabolic clinical care.
abstract: Prostate cancer (PCa) is the most common malignancy in men. Androgen deprivation therapy (ADT) plays an important role in the management of locally advanced and metastatic PCa. Its use in combination with external beam radiation and as an adjuvant therapy has resulted in improved survival in a subset of patients with locally advanced disease. In men with metastatic disease, ADT results in improvement in pain and overall quality of life. In addition to these two clinical settings where ADT has proven benefits, it is also being increasingly used in patients experiencing biochemical recurrence and those with early stage localized disease, even though no survival advantage has been demonstrated. ADT has significant adverse effects such as sexual dysfunction, decreased lean mass, increased fat mass, decreased quality of life, anemia, and osteoporosis. Recently, insulin resistance, diabetes, and metabolic syndrome have emerged as complications of ADT. Some data also suggests that ADT might be responsible for incident cardiovascular disease. Since the majority of men with PCa die of conditions other than their malignancy, recognition and management of these adverse effects is important. This paper serves as a focused review of recent studies examining the metabolic abnormalities and cardiovascular disease related to ADT.
authors.affiliation: Boston University Medical Center, Boston, MA, USA.
authors.forename: L
authors.initials: L
authors.lastname: Collins
authors.forename: N
authors.initials: N
authors.lastname: Mohammed
authors.forename: T
authors.initials: T
authors.lastname: Ahmad
authors.forename: S
authors.initials: S
authors.lastname: Basaria
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D059248:Chemoradiotherapy / Q000379:methods*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000556:secondary / Q000628:therapy*; D011788:Quality of Life
chemical_list: D000726:Androgen Antagonists